and then Glaxo Holdings plc from 1961 to 1987. His aim over all these years was to concentrate the companies' research on inventing treatments for common diseases such as those affecting the respiratory, gastrointestinal and cardiovascular systems. Under his research direction, Glaxo became one of the most successful pharmaceutical companies in the world. Medicines that he invented-salbutamol, salmeterol, beclamethasone dipropionate and fluticasone propionate-revolutionized the treatment of bronchial asthma by cutting down the incidence of acute asthma attacks, preventing hospital admissions and reducing the death rate from the disease. He also invented ranitidine for the treatment of peptic ulcer, which became the best-selling pharmaceutical product in the world. He was also responsible for the invention of sumatriptan for the treatment of migraine and ondansetron for the prevention of radiotherapy-induced nausea. David Jack was one of the most successful inventors of new medicines in the twentieth century.
student, and in 1945 he won the Physiology Medal of the Faculty of Medicine, a prize normally reserved for medical students. In 1948 he graduated BSc with first-class honours in pharmacy and pharmacology from Glasgow University. He became an assistant lecturer in experimental pharmacology in the Department of Materia Medica in Glasgow Medical School, having turned down two offers to read for a PhD, one with Professor Frank Spring (FRS 1952) , whom David was to describe as 'the most inspiring teacher I ever encountered'. Having completed a year's National Service in the Royal Army Medical Corps at the Army College of Health, he returned to the university but decided after a year to stop working with experimental animals; he resigned from his post in 1951. When he explained his reasons for resigning, namely that although he recognized the importance of animal research for human welfare, he felt it was not right for him to pursue this line of work, his head of department introduced David to Dr Tom Macrae, the Research and Development (R&D) Director of Glaxo Laboratories, Greenford, who offered him the post of research pharmacist at Glaxo, which he accepted. This started him on a career in the pharmaceutical industry that culminated in his appointment as Head of Research at Glaxo Holdings plc.
Personal and family life
David Jack was born on 22 February 1924, the youngest of six children. His father, Andrew Jack, worked in a local paper mill before becoming a coal miner. Andrew's main hobby was gardening, which became his full-time occupation for 10 years after he had to leave the mines because of ill health. His mother, Mary (née Maiden), had wished to become a school teacher but was made to work in a local flax mill by her father, who owned the mill. She and Andrew were married in 1912 and brought up six children in the difficult financial times of the 1920s and 1930s. David met his wife-to-be, Lydia Brown, when they were fellow students of pharmacy in Glasgow, where they graduated on the same day. They were married in 1952 and had two children, Moira (born in 1954) and Norma (born in 1958). Moira later had a career in Human Resources with ICI plc, and Norma's career included working in Operations and Sales at Exxon Chemicals. Moira married in 1981; Norma married in 1992 and had two sons, born in 1993 and 1997. Lydia, David's wife, graduated in pharmacy and pharmacognosy and taught pharmacognosy for several years before working as a hospital pharmacist. From 1961 onwards she also made a significant contribution to the Girl Guides movement in Hertfordshire, where she was successively District Commissioner, County Commissioner and ultimately President of the Guides.
Moira and Norma have provided the following personal recollection of their father's interests and family life outside his professional work:
Father had a wide range of interests, outside his work, to which he applied his enquiring mind.
He started playing golf as a boy on the municipal course at Markinch, where cows and sheep had to be encouraged to vacate the greens and he would do odd jobs to raise the small green fees. He was a talented player and ultimately played golf to a high level despite having little time to practice. It was no coincidence that in the 1960s we moved to Gustard Wood to live within 200 metres of the golf course! He and my mother played together and could be a deadly combination in the mixed foursomes. The Mid-Herts Golf Club Honours Boards are testament to his and their success. Although as children we did not share our father's interest in golf, we very much enjoyed sharing the pre-match fried egg sandwiches with lots of ketchup, which were his preferred Sunday morning fare. He was away working a great deal, and mother recalls a day when he was practising and a lady, spotting an unfamiliar face, came to check that he was a member. He was amused when after a short conversation she commented, 'Oh, you're Lydia's husband; well, that's all right then', and he was allowed to continue.
He followed a wide variety of sports, particularly football. Throughout his time living in England he remained faithful to Raith Rovers and often attended Luton Town matches.
Father was musical and as a boy and young man he played the cornet in the Markinch Town Band, winning many prizes. For some years it was part of the Jack family Christmas tradition that he searched out his cornet to check if he could still play! He and mother also enjoyed visits to concerts, opera and ballet.
He inherited his father's love of gardening (figure 1) and created several gardens. He took a great, if restless, interest in his plants, constantly looking to re-site them to better effect.
He was a loving father with high standards, placing great emphasis on education and effective knowledge. One of his regular sayings was 'You think with what you know.' He applied his scientific approach to our development and learning, always encouraging us to think for ourselves and work things out from 'first principles'. When we asked him a question, it was usual to be met with, 'Well, what do you think?' and be encouraged to work it out for ourselves. This could be infuriating when an immediate answer for school homework was required but has stood us in good stead as adults. Life, however, was not always serious and we have happy memories of flying (or trying to fly) homemade brown paper kites, sledging on the golf course, fishing for newts and minnows, and learning to ride bicycles. As we grew up he encouraged us to do what we wanted, to the highest level. He assumed we could do anything, and never treated us as 'girls'. He took an interest in our various activities and took pride in our achievements, even though they were different from his own. In later years he took pleasure in being part of his grandsons' lives, encouraging their learning and appreciating their successes. They in turn valued spending time with him-whether being instructed in the correct way to swing a golf club or discussing their science homework. He cared about all his family and helped to ensure his older sisters were looked after in their old age. After his retirement he became a member and then Chairman of the Committee of the Local Abbeyfield home. At this time, well-meant legislation requiring retirement homes to be upgraded caused great problems in smaller homes, where this could not be done. This caused great distress to residents, and father helped to ensure that the residents' needs were taken account of whilst the problems were resolved.
He and mother travelled extensively together. They particularly liked Italy and travelled to most parts of the country experiencing the history, culture, food and wine! He put his school Latin to good use, both translating ancient Roman inscriptions and conversing with the locals.
Father was a brilliant man but always modest about his knowledge and achievements. We remember him often saying when asked about something, 'I don't know much about this but …' and then going on to show more knowledge and understanding about the subject than many who considered themselves expert! He was very pleased when his important work was acknowledged with many awards and we know that he particularly valued being elected a Fellow of the Royal Society.
We were delighted when, in his memory and in recognition of his contribution, the Markinch Society chose to mark the house where he was born and brought up with a blue plaque and GlaxoSmithKline named its R&D site at Ware the David Jack Centre for Research & Development.
early career in the Pharmaceutical industry
The main pharmaceutical products of Glaxo Laboratories at that time were licensed in from other companies and little original research was conducted. David's job was to formulate products of salts of penicillin and supervise their transfer to production. The lessons he learned from this work on relatively insoluble compounds were to prove invaluable in his later work on aerosol suspensions of anti-asthmatic drugs. But the work was tedious and repetitive and in 1953 he decided to seek alternative employment. He became the Senior Development Pharmacist at Menley & James Ltd, a small pharmaceutical company that acted as the British agent for several overseas companies, the largest of which was Smith, Kline & French (SK&F), which took over Menley & James in 1955. David's roles at SK&F were, first, to establish UK expertise for the manufacture of long-acting preparations of Drinamyl, a mixture of amphetamine and amylobarbitone (better known as 'purple hearts') and second, to assess the scientific and medical potential of products identified for in-licensing. This involved regular visits to the US headquarters of SK&F in Philadelphia, where he learned about product development programmes.
He was also asked to devise a new method for the production of one of their products, nitrofurantoin, a urinary antiseptic, because the currently used techniques involved the use of unstable intermediates (1-3)*. David completed this work and it formed the basis for a PhD, which he successfully submitted to the University of London in 1960. It also formed the basis for his election to the Royal Institute of Chemistry.
In 1961 Professor Todd, Head of the School of Pharmacy at the Royal Technical College in Glasgow, retired; David Jack was invited to apply for his position, but his radical views In both these roles he had a determining influence on all research projects and was able to implement strategies of drug development that had been considered unacceptable by the selection committee at the Royal Technical College in 1961.
In these roles, one of his constant aims was to concentrate the company's research on treatments for common diseases such as respiratory, gastrointestinal and cardiovascular illnesses.
Because he was chairman of all the relevant product development committees, he retained personal responsibility for the selection and conduct of all drug development. Another aim on assuming his role at Allen & Hanburys was to concentrate on pharmacology-based research that would complement programmes being currently executed at Glaxo Research on steroids, antibiotics, vaccines and veterinary medicines. But he was surprised and disappointed that none of the ongoing projects at Allen & Hanburys was relevant to this plan and, moreover, that there was an absence of expertise in medicine, biochemistry and toxicology, all of which he considered essential disciplines for drug discovery and drug development. So he had to start by appointing a completely new team, although it is significant that he decided to become his own Director of Pharmacology.
David Jack installed unusually productive R&D teams at both Allen & Hanburys and then at Glaxo. He had assembled a staff of 130 at Allen & Hanburys in 1961; when he retired in 1987 there were 800 staff working in R&D at Allen & Hanburys and 3000 at Glaxo. Glaxo became one of the most successful pharmaceutical companies in the world and by 1987 the products from these research activities accounted for 75% of the turnover and profit of the company.
the discovery and develoPment of new medicines David Jack's major inventions were drugs for treating asthma (salbutamol, salmeterol, beclamethasone dipropionate and fluticasone propionate), a drug for treating peptic ulcer (ranitidine), a drug for treating radiotherapy-induced nausea (ondansetron) and a drug for treating migraine (sumatriptan). Five of these gained the Queen's Award for Technological Achievement.
The success of his research was largely based on a simple approach to project management. A primary objective was always to invent better treatments for relatively common ailments. Accordingly, each project had to contain the possibility of producing such a medicine or be directed at elucidating a physiological or pathological process whose manipulation might lead to one. Short product development times were also a characteristic of the work he undertook.
For example, salbutamol and its longer-acting analogue, salmeterol, were marketed in the UK only three and five years after their first syntheses.
New medicines for asthma
In the early 1960s, isoprenaline was the most efficient product available to treat asthma. Isoprenaline has many pharmacological actions because it activates all β-adrenoceptors. One or two inhalations produce intense bronchodilatation because the drug is actively absorbed from the airways, but its action is of short duration (1-2 hours) because it is rapidly inactivated by catechol-O-methyltransferase. Its main side effect is cardiac stimulation. A longer-acting isoprenaline analogue was an obvious research target for David Jack and his team.
β-Adrenoceptor agonists
In 1966, understanding of what was achievable was transformed when AH 3021, the saligenin analogue of isoprenaline, was found to be at least 200 times more active on bronchial muscle than heart muscle; AH 3365 (salbutamol), its tertiary butyl analogue, was even more selectively active (4-6). This unexpectedly greater selectivity was strong evidence of the subdivision of β-adrenoceptors into β 1 -and β 2 -adrenoceptors, a classification that was generally accepted from about 1970 onwards (Lands et al. 1967) . Salbutamol given by inhalation rapidly induces near-maximal bronchodilatation without significant side effects, with a duration of action of 3-4 hours. Oral doses are less effective and cause obvious tremor and tachycardia. Inhaled salbutamol was to become the most prescribed bronchodilator in the world.
However, the duration of action of salbutamol was too short to provide continuous β-agonism in the airways. This problem was solved by the invention of salmeterol. This was based on David's concept of two types of pharmacological agonism. In type 1 agonism, the target cells respond continuously to stimulation, and persistent binding of an agonist to a receptor results in continuing stimulation. Adrenoceptor stimulants and glucocorticosteroids are typical type 1 agonists. In type 2 agonism, the cell, having responded to an effective stimulus, must recover before it can respond to another stimulus. The nicotinic actions of acetylcholine at autonomic ganglia and motor endplates in skeletal muscle are examples of type 2 agonism (7). David initiated a search for a selective β 2 -receptor agonist that would bind persistently to its receptor protein because, as a type 1 agonist, it should be long-acting (8-10). Even within the Glaxo team this was considered controversial because of the large available literature on desensitization of β-adrenoceptors after continuous stimulation. But the synthesis of analogues of salbutamol with increasingly long flexible non-polar side chains resulted in the eventual synthesis of salmeterol. In large clinical trials in patients with chronic asthma, salmeterol induced near-maximal bronchodilatation lasting 8-12 hours without evidence of tolerance or use-limiting side effects. By inhibiting the release of histamine from mast cells and the histamine-induced contraction of endothelial cells in post-capillary venules, salmeterol also prevents extravasation of the plasma proteins that activate the harmful kinin and complement cascades (16).
Inhaled steroids
Beclomethasone dipropionate was the first potent topical anti-inflammatory steroid shown to have a selective action in the airways when administered by inhalation to patients with asthma (11). This was a major advance in the treatment of asthma because at usual therapeutic doses it is not accompanied by significant glucocorticoid activity elsewhere in the body, and its prolonged duration of action enables twice daily administration to be effective over 24 hours. However, a significant fraction of each dose is swallowed and absorbed from the alimentary tract into the general circulation, and this may cause systemic side effects at higher doses, especially in children. The solution to this problem was found in a drug that had already been made by Glaxo chemists for possible use in dermatology. Fluticasone propionate (FP) has a unique profile of intense anti-inflammatory activity when applied to human skin and a lack of systemic glucocorticoid activity after oral administration in the mouse, a species known to be very sensitive to oral glucocorticoids. Oral FP in both mouse and humans is quantitatively inactivated by first-pass metabolism in the liver, and the anti-inflammatory action of inhaled FP is very selective.
Combination products
Inhalers containing both salmeterol and fluticasone are of great medical importance and are now used to produce effective long-lasting bronchodilatation and control of inflammation in the airways for patients with asthma and chronic obstructive airways disease.
The clinical importance of these products for the prevention and treatment of asthma cannot be overemphasized. They diminish the number of acute asthma attacks, they prevent the need for hospital admissions from asthma and they are an important contributor to reducing the death rate from asthma, that in the UK had been one of the highest in the world.
Histamine H 2 -receptor antagonists
In 1972, James Black's team in SK&F published their finding that burimamide, a remote analogue of histamine, inhibited the gastric secretion evoked by the infusion of histamine or pentagastrin as well as that induced by food (Black et al. 1972 ). These results proved that histamine is a physiological mediator of gastric acid secretion and revealed the possibility of a new kind of medicine for treating peptic ulcers. But burimamide was not a useful medicine because it was only weakly active and poorly absorbed from the gut. It was, however, the first step towards the production of cimetidine, which, when marketed in 1976, transformed the treatment of peptic ulcers.
The only important flaw in cimetidine is that its blocking action on histamine H 2 receptors was not entirely selective. Therapeutic doses of cimetidine also inhibited oxidative drug metabolism in the liver by inhibiting cytochrome P450 and therefore could potentiate the effect of commonly used medicines such as theophylline, warfarin and phenytoin if they were administered simultaneously with it. Cimetidine was also a weak androgen antagonist, but this was not usually important at the doses used in treating peptic ulcers.
The search in Glaxo laboratories to invent orally active histamine H 2 -receptor antagonists that were not subject to SK&F patents began in 1973. It appeared from work at SK&F that a basic aromatic ring, preferably 5-methylimidazole, was essential for potent histamine H 2 antagonism. But chemists at Glaxo showed that this was not necessarily so and that the required basic centre could be a basic substituent on an aromatic ring. The outcome of this work was the invention of ranitidine, whose general structure was similar to that of cimetidine but which was five times more active (12, 13). It was also qualitatively different from cimetidine in that it did not inhibit hepatic cytochrome P450 or block androgen receptors. Ranitidine was marketed in 1981, and 10 years later it was the best-selling pharmaceutical product in the world.
Products derived from 5-hydroxytryptamine
After the success of salbutamol and beclamethasone dipropionate, David Jack encouraged work on the identification of subtypes of receptors for extracellular physiological mediators, because selective agonists and antagonists of these might be useful as medicines. The project on 5-hydroxytryptamine (5-HT) was very successful in that two important new kinds of medicines, ondansetron and sumatriptan, were invented.
Ondansetron was a specific antagonist of 5-HT 3 receptors involved in those reflexes which mediate nausea and vomiting. Normally these vomiting reflexes are protective but they become hyperactive during cancer chemotherapy, causing great distress to patients. Ondansetron was an effective antiemetic in such patients and greatly improved their tolerance of chemotherapy. It was marketed in 1990.
Sumatriptan was the first selective 5-HT 1D receptor antagonist to treat migraine. It proved to be extremely effective in controlling attacks of migraine, probably by mimicking the constrictive action of 5-HT on cerebral vessels (14, 15).
conclusion
It is interesting to note that two of the greatest drug discoverers the world has known, David Jack and James Black, were born in the same year (1924) in the same part of West Fife, came from similar family backgrounds and died within a year of each other, in 2011 and 2010 respectively. The contribution that each made to the health of mankind in the fields of respiratory, gastrointestinal and cardiovascular disease is immeasurable.
The enthusiasm that David Jack showed for science has been the catalyst for the work of many others, both in industry and in academia. His logical and systematic approach to drug discovery and development described above has been the inspiration to generations of basic and clinical scientists. Colleagues, both senior and junior, remember him with respect and also affection. The high standards that he expected from others were a reflection of his own. acknowledGements Many of the recollections above resulted from discussions with David Jack, who provided me with the factual details for this memoir. Five years before he died, he invited me to write this memoir at the appropriate time, and it has been a great honour to do so. I am also grateful to Lydia, his wife, and Moira and Norma for their contributions.
The frontispiece photograph was taken in 1992 on his election to the Fellowship. Copyright © The Royal Society.
